Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
Anni A Winckelmann, Laerke V Munk-Petersen, Thomas A Rasmussen, Jesper Melchjorsen, Thomas J Hjelholt, David Montefiori, Lars Ostergaard, Ole S Sogaard, Martin Tolstrup
PLOS ONE | PUBLIC LIBRARY SCIENCE | Published : 2013
Toll-like receptor (TLR) agonists can reactivate HIV from latently infected cells in vitro. We aimed to investigate the TLR-9 agonist, CPG 7909's in vivo effect on the proviral HIV reservoir and HIV-specific immunity. This was a post-hoc analysis of a double-blind randomized controlled vaccine trial. HIV-infected adults were randomized 1:1 to receive pneumococcal vaccines with or without 1 mg CPG 7909 as adjuvant at 0, 3 and 9 months. In patients on suppressive antiretroviral therapy we quantified proviral DNA at 0, 3, 4, 9, and 10 months (31 subjects in the CPG group and 37 in the placebo-adjuvant group). Furthermore, we measured HIV-specific antibodies, characterized T cell phenotypes and ..View full abstract
AW is supported by a scholarship from the Danish Medical Research Council. TAR is supported by a fellowship from Aarhus University. The completion of the study was further supported by The AIDS Foundation, Familien Hede Nielsens Fond, Laege Soren Segel og Hustru Johannes Forskningsfond, Ulla og Mogens Folmer Andersens Fond and Torben og Alice Frimodts Fond. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.